Darwin Global Management, Ltd. — Quarter-over-Quarter 13F Allocation Shifts Q1 2026
In Q1 2026, Darwin Global Management, Ltd. initiated 3 new positions, increased allocation to 2 existing positions, trimmed 1 position, and exited 3 positions entirely. The fund's 13F equity book declined from $4.94B to $3.77B (-23.7% QoQ) . All deltas are sourced from sequential SEC Form 13F-HR filings; share-count changes reflect explicit trading activity, while weight changes can also include price movement. This page lists every position change reported — the portfolio overview shows a summary of the top shifts.
Net Portfolio Value Change
- $4.94BPrior quarter
- $3.77BCurrent quarter
- $-1.17BNet delta
- -23.7%% change
New Position Initiations Q1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Allocation Weight | History |
|---|---|---|---|
| REVOLUTION MEDICINES INC | RVMD | 5.44% | History → |
| ROIVANT SCIENCES LTD. | ROIV | 4.76% | History → |
| DIANTHUS THERAPEUTICS INC | DNTH | 0.04% | History → |
Largest Allocation Increases Q1 2026
Largest portfolio-weight increases in existing positions. Share-count delta is shown separately so price-only re-weighting can be distinguished from active adds.
| Company | Ticker | Δ Weight | Δ Shares | History |
|---|---|---|---|---|
| ABIVAX S.A. | ABVX | +0.43% | +9.13% | History → |
| BELITE BIO INC | BLTE | +2.24% | +0.98% | History → |
Largest Allocation Reductions Q1 2026
Largest portfolio-weight decreases in existing positions (positions kept open at a lower allocation).
| Company | Ticker | Δ Weight | Δ Shares | History |
|---|---|---|---|---|
| INSMED INCORPORATED | INSM | -5.45% | -19.72% | History → |
Exited Positions Q1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| CIDARA THERAPEUTICS INC | SYN_171757206 | 4.46% |
| WAVE LIFE SCIENCES LTD. | WVE | 2.53% |
| CAPRICOR THERAPEUTICS INC | CAPR | 0.47% |
Methodology & FAQ
How Darwin Global Management, Ltd. Quarterly Changes Are Computed
Each row above is computed by joining the most recent 13F-HR filing for Darwin Global Management, Ltd. against the immediately preceding quarterly filing for the same fund. Portfolio weights are normalized to exclude listed options for comparability. A complete description of the methodology — including how confidential treatment filings are handled and why share count rather than weight is the cleaner trading signal — is documented in the Methodology.
Which positions did Darwin Global Management, Ltd. initiate in Q1 2026?
Darwin Global Management, Ltd. established 3 new positions in Q1 2026: REVOLUTION MEDICINES INC (RVMD, 5.44%), ROIVANT SCIENCES LTD. (ROIV, 4.76%), DIANTHUS THERAPEUTICS INC (DNTH, 0.04%).
Which existing positions saw the largest allocation increases for Darwin Global Management, Ltd. in Q1 2026?
The largest portfolio-weight increases in existing positions were: ABIVAX S.A. (ABVX, +0.43% weight, +9.13% shares), BELITE BIO INC (BLTE, +2.24% weight, +0.98% shares).
Which positions did Darwin Global Management, Ltd. fully exit in Q1 2026?
Darwin Global Management, Ltd. fully exited 3 positions in Q1 2026: CIDARA THERAPEUTICS INC (SYN_171757206, last-reported weight 4.46%), WAVE LIFE SCIENCES LTD. (WVE, last-reported weight 2.53%), CAPRICOR THERAPEUTICS INC (CAPR, last-reported weight 0.47%).
Which existing positions saw the largest allocation reductions for Darwin Global Management, Ltd. in Q1 2026?
The largest portfolio-weight reductions in positions kept open were: INSMED INCORPORATED (INSM, -5.45% weight, -19.72% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity.